# US 2026/0076953 A1 · Methods of diagnosing and treating adhd in biomarker positive subjects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076953 A1
- Document ID: US20260076953A1
- Status: Published application
- Kind: A1
- Application number: 19/335,458
- Filed: 2025-09-22
- Published: 2026-03-19
- Earliest claimed: 2017-04-19
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Garry A. Neil; Liza Squires; Hakon Hakonarson
- Web page: https://patentgrep.com/patent/US20260076953A1

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.

## Claims

### Claim 1

A method of treating attention deficit hyperactivity disorder (ADHD) in a subject, the method comprising administering fasoracetam to the subject, wherein the subject has at least one copy number variation (CNV) in a mGluR network gene selected from the group consisting of CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8.

### Claim 2 (depends on 1)

The method of claim 1,
wherein fasoracetam is administered to the subject in an amount effective to result in a clinical general impression improvement (CGI-I) score of 1 or 2 after at least four weeks of treatment and/or an improvement of at least 25% in an ADHD rating scale score after at least four weeks of treatment.

### Claim 3 (depends on 1)

The method of claim 1, wherein the CNV is in CNTN4.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a pediatric, adolescent, or adult subject.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein at least one of the following applies:
(a) the fasoracetam is administered at a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, and wherein the dose is administered once, twice, or three times daily; and
(b) the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily, such as 100-200 mg twice daily or 200-400 mg twice daily.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the fasoracetam is administered in combination with at least one of the following:
(i) a stimulant, such as methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, or lisdexamphetamine; and/or in combination with
(ii) a nonstimulant, such as atomoxetine, clonidine, or guanfacine; and/or in combination with an antidepressant, such as fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, norepinephrine and dopamine reuptake inhibitors, or monoamine oxidase inhibitors; and/or in combination with
(iii) an anxiolytic, such as barbiturates, pregabalin, or benzodiazepines, including chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam, or midazolam; and/or in combination with
(iv) an anti-psychotic, such as aripiprazole or risperidone; and/or in combination with
(v) a beta blocker, such as acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol, or timolol.

### Claim 10 (depends on 1)

The method of claim 1, wherein the fasoracetam is administered in combination with non-pharmaceutical therapy, optionally wherein the non-pharmaceutical therapy is selected from the group consisting of brain stimulation, repetitive transcranial magnetic stimulation, magnetic seizure therapy, and deep brain stimulation.

### Claim 11 (depends on 1)

The method of claim 1, wherein the fasoracetam is administered as a monotherapy.

### Claim 12 (depends on 11)

The method of claim 11, wherein the fasoracetam is administered after washout of other ADHD medications.

### Claim 13 (depends on 1)

The method of claim 1, wherein a decrease in the dosage of other ADHD medications is made after the fasoracetam is administered.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein at least one of the following applies:
(i) the subject has symptoms of anger control issues wherein administration of fasoracetam increases anger control in the subject;
(ii) the subject has disruptive behavior wherein administration of fasoracetam reduces disruptive behavior in the subject;
(iii) the subject has risk taking behaviors wherein administration of fasoracetam reduces risk taking behaviors in the subject;
(iv) the subject has difficulty completing work wherein administration of fasoracetam improves the ability of the subject to complete work: or
(v) the subject has inappropriate movements or sounds/noise making wherein administration of fasoracetam reduces inappropriate movements or sounds/noise making in the subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein at least one of the following applies:
(a) treatment with the fasoracetam increases anger control in the subject,
(b) treatment with the fasoracetam reduces disruptive behavior in the subject;
(c) treatment with the fasoracetam improves the subject's ability to complete work;
(d) treatment with the fasoracetam reduces inappropriate movements or sounds/noise making in the subject.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject has at least one selected from the group consisting of disruptive behavior, risk taking behavior, difficulty completing work, and inappropriate movements or sounds/noise making.

### Claim at position 17

18-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the CNV is detected by a process comprising
analyzing a nucleic acid obtained from the subject for a genetic alteration in at least one gene selected from the group consisting of CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8, and
wherein the method comprises obtaining results of a genetic test prior to initial administration of the fasoracetam.

### Claim 26 (depends on 1)

The method of claim 1, wherein the CNV is a duplication.

### Claim 27 (depends on 1)

The method of claim 1, wherein the CNV is a deletion.

### Claim 28

A method for diagnosing attention deficit hyperactivity disorder (ADHD) in a human subject comprising detecting in a nucleic acid sample obtained from the subject at least one CNV in a subset of mGluR network genes consisting of CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8 by contacting the nucleic acid sample with a set of probes or primers of sufficient length and composition to detect a duplication or deletion CNV in CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8; and diagnosing the subject as having ADHD when the presence of at least one CNV in the nucleic acid sample is detected.

### Claim 29

(canceled)

### Claim 30

A method for detecting copy number variations (CNVs) in a subset of metabotropic glutamate receptor (mGluR) network genes consisting of CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8 in a human subject comprising contacting a nucleic acid sample obtained from the subject with a set of probes or primers of sufficient length and composition to detect a duplication or deletion CNV in each of CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8.

### Claim 31 (depends on 28)

The method of claim 28, wherein the mGluR network gene is CNTN4.

### Claim 32 (depends on 28)

The method of any one of claim 28, wherein the subject has at least one selected from the group consisting of disruptive behavior, difficulty completing work, behaviors associated with risk taking, inappropriate movements, inappropriate sounds/noise making, and hyperactivity.

### Claim at position 26

33-49. (canceled)
